UNUM THERAPEUTICS WEDBUSH PACGROW HEALTHCARE CONFERENCE AUGUST 2019 FORWARD-LOOKING STATEMENTS AND RISK FACTORS This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward looking statements. All statements other than statements of historical fact could be deemed fo ...

Platform and Pipeline - Unum Therapeutics' ACTR/BOXR platforms are designed to improve targeting and functionality of T cell therapies[5,8] - The company is advancing a pipeline of product candidates in hematologic cancers and solid tumors, including ACTR707, ACTR087, and BOXR1030[6] - BOXR platform addresses the tumor microenvironment (TME) challenge by improving T cell functionality[14,15] Clinical Trial Results (ACTR707 in r/r NHL) - Preliminary Phase 1 trial data for ACTR707 in relapsed/refractory (r/r) Non-Hodgkin's Lymphoma (NHL) showed an overall response rate (ORR) of 64% (9/14 patients) across Cohorts 1-3[25] - Complete responses (CR) were observed in 36% of patients (5/14) across Cohorts 1-3[25] - The trial showed a favorable safety profile with no dose-limiting toxicities (DLTs), severe neurologic events, or Cytokine Release Syndrome (CRS) observed in Cohorts 1-3[27] Clinical Trial Results (ACTR087 in Multiple Myeloma) - Phase 1 trial of ACTR087 in multiple myeloma completed three dose levels in 2018 at very low antibody doses and 30M ACTR+ T cells, with no dose-limiting toxicities or severe CRS or neurologic events observed[33] Solid Tumor Programs - ACTR707 is also being evaluated in a Phase 1 trial for advanced HER2+ cancers[6,37] - BOXR1030, a GPC3-targeted CAR-T, is engineered for enhanced metabolism in the solid tumor microenvironment and has shown promising preclinical activity[39,42] Upcoming Milestones - Several milestones are anticipated in 4Q 2019, including reporting preliminary Cohort 3 results and Cohort 1-4 results from ATTCK-20-03, reporting safety and efficacy results from Phase 1 (ATTCK-20-02), reporting enrollment status and safety in Phase 1 (ATTCK-34-01), progress BOXR-1030 towards IND[43]

Unum Therapeutics Inc. (UMRX) Q2 2019 Earnings Conference Call August 12, 2019 4:30 PM ET Corporate Participants Chuck Wilson - Chief Executive Officer Jessica Sachs - Chief Medical Officer Seth Ettenberg - Chief Scientific Officer Matt Osborne - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Peter Lawson - SunTrust Robinson Leo Li - Cowen Operator Good afternoon, and welcome to the Unum Therapeutics' Quarterly Investor Conference Call. Today, we will be showing update ...

PART I—FINANCIAL INFORMATION This section covers unaudited financial statements, management's analysis, market risk, and internal controls [Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) Unaudited financial statements reflect a decrease in total assets and an increased net loss for the period, primarily due to cash consumption and higher operating expenses [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) This section presents the company's financial position, including assets, liabilities, and equity, as of June 30, 2019, and December 31, 2018 | Financial Metric | June 30, 2019 (in thousands) | December 31, 2018 (in thousands) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $55,863 | $55,671 | | Marketable securities | $0 | $22,923 | | Total current assets | $58,598 | $81,002 | | Total assets | $69,308 | $85,927 | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $24,307 | $24,945 | | Total liabilities | $29,550 | $25,693 | | Accumulated deficit | ($114,266) | ($92,059) | | Total stockholders' equity | $39,758 | $60,234 | [Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) This section details the company's revenues, expenses, and net loss for the three and six months ended June 30, 2019 and 2018 | Metric (in thousands, except per share data) | Three Months Ended June 30, 2019 | Three Months Ended June 30, 2018 | Six Months Ended June 30, 2019 | Six Months Ended June 30, 2018 | | :--- | :--- | :--- | :--- | :--- | | Collaboration revenue | $3,138 | $1,666 | $6,191 | $3,886 | | Research and development | $10,617 | $9,126 | $23,020 | $17,268 | | General and administrative | $3,062 | $1,979 | $5,553 | $3,043 | | Loss from operations | ($10,541) | ($9,439) | ($22,382) | ($16,425) | | Net loss | ($10,516) | ($9,023) | ($22,207) | ($15,758) | | Net loss per share, basic and diluted | ($0.34) | ($0.31) | ($0.73) | ($0.80) | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) This section outlines the company's cash inflows and outflows from operating, investing, and financing activities for the six months ended June 30, 2019 and 2018 | Cash Flow Activity (in thousands) | Six Months Ended June 30, 2019 | Six Months Ended June 30, 2018 | | :--- | :--- | :--- | | Net cash used in operating activities | ($22,862) | ($15,894) | | Net cash provided by (used in) investing activities | $22,946 | ($35,445) | | Net cash provided by financing activities | $108 | $69,776 | | Net increase (decrease) in cash | $192 | $18,437 | | Cash, cash equivalents and restricted cash at end of period | $57,118 | $48,037 | [Notes to Unaudited Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Consolidated%20Financial%20Statements) This section provides additional details and explanations supporting the unaudited consolidated financial statements - The company is a clinical-stage biopharmaceutical firm focused on cell therapies for cancer, utilizing its proprietary ACTR and BOXR platforms[24](index=24&type=chunk) - The company has incurred recurring losses since inception, with a **net loss of $22.2 million** for the six months ended June 30, 2019, and an **accumulated deficit of $114.3 million**; management expects cash on hand to be sufficient for at least 12 months[27](index=27&type=chunk) - Under its collaboration agreement with Seattle Genetics, the company recognized **revenue of $6.2 million** for the six months ended June 30, 2019, with an estimated **$42.4 million** remaining performance obligation[68](index=68&type=chunk) - As of June 30, 2019, the company had non-cancelable minimum purchase commitments totaling **$2.4 million** over the following 12 months[87](index=87&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management analyzes the company's financial condition, operational results, and liquidity, highlighting cell therapy development, clinical program updates, and key financial metrics [Overview](index=20&type=section&id=Overview) This section provides a high-level introduction to the company's business, strategic focus, and recent significant developments - Unum is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer using its proprietary Antibody-Coupled T cell Receptor (ACTR) and Bolt-On Chimeric Receptor (BOXR) platforms[97](index=97&type=chunk) - The company's most advanced programs, ATTCK-20-2 and ATTCK-20-03, test ACTR087 or ACTR707 with rituximab in patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (r/r NHL)[99](index=99&type=chunk) - In July 2019, the FDA placed a **clinical hold** on the ATTCK-20-2 trial (ACTR087) following a safety report of a patient who experienced serious adverse events and a fatal outcome[101](index=101&type=chunk) [Results of Operations](index=24&type=section&id=Results%20of%20Operations) This section analyzes the company's financial performance, including revenue, expenses, and net loss, for the three and six months ended June 30, 2019 and 2018 | Metric (in thousands) | Three Months Ended June 30, 2019 | Three Months Ended June 30, 2018 | Change | | :--- | :--- | :--- | :--- | | Collaboration Revenue | $3,138 | $1,666 | $1,472 | | Research and Development | $10,617 | $9,126 | $1,491 | | General and Administrative | $3,062 | $1,979 | $1,083 | | Net Loss | ($10,516) | ($9,023) | ($1,493) | | Metric (in thousands) | Six Months Ended June 30, 2019 | Six Months Ended June 30, 2018 | Change | | :--- | :--- | :--- | :--- | | Collaboration Revenue | $6,191 | $3,886 | $2,305 | | Research and Development | $23,020 | $17,268 | $5,752 | | General and Administrative | $5,553 | $3,043 | $2,510 | | Net Loss | ($22,207) | ($15,758) | ($6,449) | - The increase in R&D expenses for the six months ended June 30, 2019, was primarily due to increased clinical activity, patient manufacturing, and personnel-related costs from increased headcount[140](index=140&type=chunk)[142](index=142&type=chunk) - The increase in G&A expenses for the six months ended June 30, 2019, was mainly driven by higher professional fees (legal, audit, accounting), personnel costs, and insurance expenses associated with operating as a public company[143](index=143&type=chunk) [Liquidity and Capital Resources](index=27&type=section&id=Liquidity%20and%20Capital%20Resources) This section discusses the company's cash position, funding sources, and ability to meet its short-term and long-term financial obligations - As of June 30, 2019, the company had **$55.9 million** in cash and cash equivalents and **$15.0 million** available under its loan and security agreement[147](index=147&type=chunk) - Management expects that current cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements into **early 2021**[163](index=163&type=chunk) - Net cash used in operating activities was **$22.9 million** for the six months ended June 30, 2019, an increase from **$15.9 million** in the same period of 2018, primarily due to a higher net loss and changes in operating assets and liabilities[150](index=150&type=chunk)[151](index=151&type=chunk) - The company amended its loan agreement in June 2019 to extend the available date for borrowings to June 30, 2020; no amounts had been borrowed as of June 30, 2019[158](index=158&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=31&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, Unum Therapeutics is not required to provide quantitative and qualitative disclosures about market risk - As a smaller reporting company, Unum Therapeutics is not required to provide quantitative and qualitative disclosures about market risk[171](index=171&type=chunk) [Controls and Procedures](index=31&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2019, with no material changes to internal control over financial reporting - The company's management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of June 30, 2019[172](index=172&type=chunk) - No material changes in internal control over financial reporting occurred during the three months ended June 30, 2019[173](index=173&type=chunk) PART II—OTHER INFORMATION This section provides additional information including legal proceedings, risk factors, equity sales, and exhibits [Legal Proceedings](index=33&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings - The company is not currently a party to any material legal proceedings[176](index=176&type=chunk) [Risk Factors](index=33&type=section&id=Item%201A.%20Risk%20Factors) The company highlights significant risks, including high dependency on lead product candidates, the FDA clinical hold on ACTR087, and potential for adverse side effects in clinical trials - The company's business is highly dependent on the success of its lead product candidates, including ACTR707 and potential BOXR candidates like BOXR1030[178](index=178&type=chunk) - A Phase 1 clinical trial for ACTR087 was placed on **clinical hold** by the FDA in July 2019 following a safety report, highlighting a significant risk to the ACTR platform[178](index=178&type=chunk) - The company's product candidates may cause undesirable side effects such as Cytokine Release Syndrome (CRS), neurotoxicity, and other issues that could halt clinical development, as observed in the ATTCK-20-2 trial which led to a clinical hold[186](index=186&type=chunk)[187](index=187&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=35&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details the use of proceeds from the March 2018 IPO and private placement, including amounts used for clinical development and the anticipated funding timeline - The company raised **net proceeds of approximately $63.9 million** from its IPO and **$5.0 million** from a concurrent private placement in March/April 2018[191](index=191&type=chunk) - As of June 30, 2019, the company has used approximately **$45.4 million** of the net proceeds for clinical development, research, and working capital[191](index=191&type=chunk) - The company anticipates the remaining net proceeds will fund operating expenses and capital expenditures into **early 2021**[191](index=191&type=chunk) [Exhibits](index=36&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including agreements, contracts, and officer certifications

Unum Therapeutics Inc. (UMRX) Q1 2019 Results Earnings Conference Call May 13, 2019 8:00 AM ET Company Participants Stephanie Ascher - Investor Relations Chuck Wilson - Chief Executive Officer John Green - Vice President of Finance Michael Vasconcelles - Chief Medical Officer Seth Ettenberg - Chief Scientific Officer Conference Call Participants Peter Lawson - SunTrust Yaron Werber - Cowen Operator Good day, ladies and gentlemen, and welcome to the Unum Therapeutics' First Quarter 2019 Results Conference Ca ...

Table of Contents Emerging growth company ☒ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38443 UNUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) D ...

Unum Therapeutics Inc. (UMRX) Q4 2018 Results Earnings Conference Call March 28, 2019 8:00 AM ET Company Participants Stephanie Ascher - Investor Relations Chuck Wilson - Chief Executive Officer John Green - Vice President of Finance Michael Vasconcelles - Chief Medical Officer Seth Ettenberg - Chief Scientific Officer Conference Call Participants Peter Lawson - SunTrust Robinson Humphrey David Nierengarten - Wedbush Securities Operator Good day, ladies and gentlemen, and welcome to the Unum Therapeutics' F ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |-----------------------------------------------------------------------------|----------------------------------------------------------------------- ...

UNUM THERAPEUTICS CORPORATE PRESENTATION MARCH 2019 FORWARD-LOOKING STATEMENTS AND RISK FACTORS This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward looking statements. All statements other than statements of historical fact could be deemed forward-looking, i ...